מינג'ובי 200 מ"ג - Minjuvi 200mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01FX Other monoclonal antibodies and antibody drug conjugates | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | ת××-×ר××× - I.V | ||||||||||||||||||
| צ×רת ××× ×× | ×××§× ×××× ×ª ת×××¡× ×ר×××ת ××¢×ר××, POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | MINJUVI is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). | ||||||||||||||||||
| |||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××× ×'××× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | INCYTE BIOSCIENCES INTERNATIONAL SÃRL, SWITZERLAND |
| ×©× ××¢× ×ר×ש×× | MEDISON PHARMA LTD |
| ר×ש××× | ת×ר×× ××ש×: 7/2021. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 12/02/2024 |
השינוי האחרון נעשה בֹ־17 ביוני 2025 ב־11:25